Almirall SA has reported first-quarter sales of €209.1 million, narrowly missing analyst consensus estimates of €209.34 million. Total revenue reached €209.24 million, falling short of expectations at €209.45 million, though core dermatology products demonstrated robust performance.
Key Financial Metrics
EBITDA climbed to €67.5 million, surpassing the consensus forecast of €66.7 million. EBIT hit €30.0 million, exceeding projections of €29.3 million. Net income, however, came in at €15.3 million, below the anticipated €19.1 million, primarily due to costs from a non-recurring interest rate swap settlement.
Dermatology Segment Drives Growth
The Focus Dermatology division recorded sales of €179.7 million, reflecting a strong 16.3% year-over-year increase. Key products within the psoriasis and broader portfolio contributed significantly: Ebglyss generated €41.9 million in sales, Ilumetri €61.6 million, and Wynzora €9.3 million. Seysara posted €3.9 million overall, while Klisyri achieved €7.4 million.
Updated 2026 Guidance
Almirall raised its full-year sales growth outlook for 2026 to 9-12%, targeting a range of €1.208 billion to €1.241 billion. EBITDA guidance now spans €270 million to €290 million. This compares to analyst consensus estimates of €1.303 billion in sales and €280.3 million in EBITDA.
Pipeline Advancements
The company announced that its anti-IL-13/OX40L bispecific monoclonal antibody candidate has entered Phase 1 clinical trials for atopic dermatitis treatment.
